Literature DB >> 7633877

Management of systemic vasculitis: contribution of scintigraphic imaging to evaluation of disease activity and classification.

H Reuter1, E P Wraight, F J Qasim, C M Lockwood.   

Abstract

The use of radio-isotope-labelled leucocyte scans has become established as a non-invasive and accurate means of diagnosing a variety of inflammatory conditions. We report a retrospective study on leucocyte imaging in the management of 50 patients with systemic vasculitis. Leucocyte imaging was useful for detecting unsuspected sites of disease and monitoring disease activity. Scintigraphy was superior to conventional radiography or CT scanning for detecting and monitoring vasculitic involvement of the respiratory tract. The scans were useful for differentiating between Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). There was a close and statistically significant relationship between the clinical diagnosis of WG and nasal uptake on leucocyte scans (p < 0.01), whereas in patients with MPA it was rare. Anti-proteinase 3 autoantibody specificity correlated significantly with nasal uptake of labelled leucocytes (p < 0.03). Leucocyte imaging is a useful non-invasive investigation in patients with systemic vasculitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7633877

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  2 in total

1.  Radiolabeled leucocyte imaging in diffuse granulomatous involvement of the meninges in Wegener's granulomatosis: scintigraphic findings and their role in monitoring treatment response to specific immunotherapy (humanized monoclonal antilymphocyte antibodies).

Authors:  J M Murphy; K K Balan; A Toms; B Gomez-Anson; M Lockwood
Journal:  AJNR Am J Neuroradiol       Date:  2000-09       Impact factor: 3.825

2.  Clinical value of gallium-67 scintigraphy in assessment of disease activity in Wegener's granulomatosis.

Authors:  R H J A Slart; P L Jager; L Poot; D A Piers; J-W Cohen Tervaert; C A Stegeman
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.